Drug Profile
Amifostine/pilocarpine - Cellix Bio
Alternative Names: CLX-156Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Cellix Bio
- Class Alkaloids; Antiglaucomas; Antineoplastics; Chemoprotectants; Eye disorder therapies; Furans; Imidazoles; Miotics; Organothiophosphorus compounds; Small molecules
- Mechanism of Action Muscarinic receptor agonists; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Presbyopia
- Discontinued Xerostomia
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Presbyopia in India
- 24 Apr 2018 Discontinued - Preclinical for Xerostomia in India (unspecified route) (Cellix Bio pipeline, April 2018)
- 24 Apr 2018 Preclinical trials in Presbyopia in India (unspecified route), prior to April 2018 (Cellix Bio pipeline, April 2018)